Physician profile
Jin Li
NPI 1710974357
$96,972.36
in general payments reported to CMS, 2019-2025
26 companies · $9,553 in 2025
The $9,553 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $891 · 2020: $9,418 · 2021: $16K · 2022: $15K · 2023: $29K · 2024: $17K · 2025: $9,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $42K · Consulting Fee: $6,370 · Travel and Lodging: $4,310 · Food and Beverage: $2,855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,137.50 |
| Consulting Fee | $6,370.00 |
| Travel and Lodging | $4,309.83 |
| Food and Beverage | $2,855.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $41,357.08 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $40,448.52 | 2022-2025 | Ultomiris |
| Allergan, INC. | $12,625.25 | 2020-2022 | |
| Bausch Health US, LLC | $500.00 | 2019 | |
| Biogen, INC. | $337.58 | 2019-2025 | Skyclarys, Spinraza |
| Lilly USA, LLC | $214.52 | 2021-2023 | Emgality, Reyvow |
| Neurocrine Biosciences, INC. | $163.43 | 2023 | Ingrezza |
| Globus Medical, INC. | $153.98 | 2025 | Senza |
| Ucb, INC. | $137.84 | 2025 | |
| Gilead Sciences, INC. | $125.00 | 2019 | |
| Eisai INC. | $125.00 | 2023 | |
| Depuy Synthes Sales INC. | $115.74 | 2019 | |
| Sarepta Therapeutics, INC. | $83.00 | 2025 | |
| Argenx US, INC. | $77.70 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Merz Pharmaceuticals, LLC | $76.82 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $74.48 | 2022 | |
| Medtronic USA, INC. | $67.63 | 2020 | |
| Alnylam Pharmaceuticals INC. | $57.85 | 2022-2023 | Onpattro |
| Upsher-Smith Laboratories LLC | $56.47 | 2020-2021 | |
| Pfizer INC. | $44.42 | 2023 | |
| Amgen INC. | $33.39 | 2021 | |
| Genentech USA, INC. | $23.10 | 2022 | |
| Csl Behring | $22.25 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.22 | 2021 | |
| Celgene Corporation | $15.32 | 2022 | |
| Currax Pharmaceuticals LLC | $14.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jin Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.